Industry
Biotechnology
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Loading...
Open
35.87
Mkt cap
2B
Volume
427K
High
39.63
P/E Ratio
3.61
52-wk high
47.97
Low
33.00
Div yield
N/A
52-wk low
8.43
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 2:54 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 8:52 pm
Portfolio Pulse from Benzinga Newsdesk
May 02, 2024 | 9:06 am
Portfolio Pulse from Benzinga Newsdesk
March 26, 2024 | 2:18 pm
Portfolio Pulse from Benzinga Newsdesk
March 26, 2024 | 10:10 am
Portfolio Pulse from Benzinga Newsdesk
March 18, 2024 | 5:11 pm
Portfolio Pulse from Benzinga Newsdesk
March 18, 2024 | 12:02 pm
Portfolio Pulse from Avi Kapoor
March 05, 2024 | 3:56 pm
Portfolio Pulse from Benzinga Newsdesk
March 01, 2024 | 5:30 pm
Portfolio Pulse from Benzinga Newsdesk
March 01, 2024 | 4:10 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.